

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	RNA	<p>Studies in cell culture identified 7-deazapurine purine nucleoside-based inhibitors of RNA synthesis that could help treat cancer. In a panel of human cancer cell lines, the most potent compounds in the series caused 50% growth inhibition at concentrations in the 16–96 nM range. The potencies were comparable to or better than that of clofarabine. Next steps include <i>in vivo</i> efficacy and toxicology studies.</p> <p>Clolar clofarabine, a second-generation purine nucleoside analog from Genzyme Corp. is marketed to treat acute lymphoblastic leukemia (ALL) and is under review for acute myelogenous leukemia (AML).</p> <p>At least two other purine nucleotide analogs are marketed to treat various forms of leukemia and lymphoma.</p> <p>SciBX 3(1); doi:10.1038/scibx.2010.9 Published online Jan. 7, 2010</p>	<p>Patent applications filed; contact Palacký University for licensing inquiries</p>	<p>Naus, P. <i>et al. J. Med. Chem.</i>; published online Nov. 24, 2009; doi:10.1021/jm901428k</p> <p>Contact: Michal Hocek, Academy of Sciences of the Czech Republic, Prague, Czech Republic e-mail: hocek@uochb.cas.cz</p>